

# CITATION REPORT

List of articles citing

**Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity**

**DOI: 10.1111/dom.13120**

**Diabetes, Obesity and Metabolism, 2018, 20, 610-619.**

**Source:** <https://exaly.com/paper-pdf/69606376/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
91	Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects. <i>Clinical Pharmacokinetics</i> , <b>2017</b> , 56, 1391-1401	6.2	26
90	Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. <i>Diabetologia</i> , <b>2017</b> , 60, 1390-1399	10.3	32
89	Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes. <i>Expert Opinion on Biological Therapy</i> , <b>2018</b> , 18, 343-351	5.4	7
88	Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 610-619	6.7	69
87	GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. <i>Cardiovascular Diabetology</i> , <b>2018</b> , 17, 157	8.7	60
86	Bidirectional Relationship between Gastric Emptying and Plasma Glucose Control in Normoglycemic Individuals and Diabetic Patients. <i>Journal of Diabetes Research</i> , <b>2018</b> , 2018, 1736959	3.9	12
85	The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients. <i>International Journal of Clinical Practice</i> , <b>2018</b> , 72, e13274	2.9	5
84	Semaglutide for the Treatment of Type 2 Diabetes Mellitus. <i>Journal of Pharmacy Technology</i> , <b>2018</b> , 34, 281-289	0.6	1
83	A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin. <i>Diabetes Care</i> , <b>2018</b> , 41, 1926-1937	14.6	34
82	The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis. <i>Endocrine</i> , <b>2018</b> , 62, 535-545 <sup>4</sup>		9
81	Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist. <i>Clinical Pharmacokinetics</i> , <b>2018</b> , 57, 1529-1538	6.2	13
80	Application of Permeation Enhancers in Oral Delivery of Macromolecules: An Update. <i>Pharmaceutics</i> , <b>2019</b> , 11,	6.4	71
79	Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity. <i>Current Obesity Reports</i> , <b>2019</b> , 8, 284-291	8.4	14
78	Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials. <i>Clinical Pharmacokinetics</i> , <b>2019</b> , 58, 1205-1214	6.2	1
77	Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes. <i>Current Diabetes Reports</i> , <b>2019</b> , 19, 13	5.6	14
76	The Discovery and Development of Liraglutide and Semaglutide. <i>Frontiers in Endocrinology</i> , <b>2019</b> , 10, 155	5.7	181
75	Semaglutide as a promising antiobesity drug. <i>Obesity Reviews</i> , <b>2019</b> , 20, 805-815	10.6	33

74	Diabetic Gastroparesis and Glycaemic Control. <i>Current Diabetes Reports</i> , <b>2019</b> , 19, 153	5.6	11
73	Gastrointestinal hormones and regulation of gastric emptying. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , <b>2019</b> , 26, 3-10	4	32
72	Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus. <i>Canadian Journal of Diabetes</i> , <b>2020</b> , 44, 93-102	2.1	14
71	A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2020</b> , 45 Suppl 1, 17-27	2.2	16
70	Glucagon-like peptide-1 receptor agonists and the appropriate measurement of gastric emptying. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2504-2506	6.7	8
69	Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 2125-2135	4	6
68	Enteroendocrine Hormone Secretion and Metabolic Control: Importance of the Region of the Gut Stimulation. <i>Pharmaceutics</i> , <b>2020</b> , 12,	6.4	12
67	Berberine compounds improves hyperglycemia via microbiome mediated colonic TGR5-GLP pathway in db/db mice. <i>Biomedicine and Pharmacotherapy</i> , <b>2020</b> , 132, 110953	7.5	7
66	Weight-centric pharmacological management of type 2 diabetes mellitus - An essential component of cardiovascular disease prevention. <i>Journal of Diabetes and Its Complications</i> , <b>2020</b> , 34, 107619	3.2	7
65	Insights into incretin-based therapies for treatment of diabetic dyslipidemia. <i>Advanced Drug Delivery Reviews</i> , <b>2020</b> , 159, 34-53	18.5	11
64	Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	4
63	Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. <i>Advances in Experimental Medicine and Biology</i> , <b>2021</b> , 1307, 171-192	3.6	11
62	The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 754-762	6.7	29
61	Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA-1 Study). <i>Diabetes Therapy</i> , <b>2021</b> , 12, 955-964	3.6	2
60	Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1594-1603	6.7	12
59	Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects. <i>Clinical Pharmacokinetics</i> , <b>2021</b> , 60, 1171-1185	6.2	3
58	Gastric Sensory and Motor Functions and Energy Intake in Health and Obesity-Therapeutic Implications. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	5
57	Glucagon-Like Peptide-1 Receptor Activators. 1-69		

56	Novel Therapeutical Approaches to Managing Atherosclerotic Risk. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	4
55	Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. <i>Advances in Therapy</i> , <b>2021</b> , 38, 2821-2839	4.1	10
54	Precision Medicine for Obesity. <i>Digestive Disease Interventions</i> , <b>2021</b> , 05, 239-248	0.2	4
53	A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes. <i>Drugs</i> , <b>2021</b> , 81, 1003-1030	12.1	7
52	Lipid effects of glucagon-like peptide 1 receptor analogs. <i>Current Opinion in Lipidology</i> , <b>2021</b> , 32, 191-199	4.4	3
51	Response to the letter from Horowitz et al. to the Editor relating to the publication 'Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes' by Dahl et al. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2414-2416	6.7	
50	Potential for Gut Peptide-Based Therapy in Postprandial Hypotension. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	1
49	Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjects: an open-label, one-sequence crossover, single-center, multiple-dose, two-part trial. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2021</b> , 17, 1139-1148	5.5	4
48	Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2752-2762	6.7	4
47	Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. <i>Diabetes, Obesity and Metabolism</i> , <b>2022</b> , 24, 94-105	6.7	2
46	Formulation strategies to improve the efficacy of intestinal permeation enhancers. <i>Advanced Drug Delivery Reviews</i> , <b>2021</b> , 177, 113925	18.5	3
45	Docosahexaenoic acid-rich fish oil prevented insulin resistance by modulating gut microbiome and promoting colonic peptide YY expression in diet-induced obesity mice. <i>Food Science and Human Wellness</i> , <b>2022</b> , 11, 177-188	8.3	2
44	Application in medicine: obesity and satiety control. <b>2021</b> , 629-664		
43	The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , <b>2021</b> , 12, 2042018821989238	4.5	8
42	Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?. <i>Current Obesity Reports</i> , <b>2021</b> , 10, 14-30	8.4	31
41	Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists. <i>American Journal of Health-System Pharmacy</i> , <b>2021</b> , 78, 556-567	2.2	4
40	Long-acting glucagon-like peptide-1 receptor agonist-status December 2018. <i>Annals of Translational Medicine</i> , <b>2019</b> , 7, 83	3.2	5
39	An Overview of Prospective Drugs for Type 1 and Type 2 Diabetes. <i>Current Drug Targets</i> , <b>2020</b> , 21, 445-457	4.5	2

38	SUSTAINable management of type 2 diabetes: feasibility of use and safety of semaglutide. <i>Annals of Translational Medicine</i> , <b>2018</b> , 6, 129	3.2	
37	Antidiabetic herbal biomolecules. <b>2022</b> , 407-434		
36	An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning. <i>Iranian Journal of Basic Medical Sciences</i> , <b>2020</b> , 23, 556-568	1.8	4
35	GLP-1 Receptor Agonists as Adjunctive Treatment for Type 1 Diabetes: Renewed Opportunities through Tailored Approaches?. <i>Diabetes, Obesity and Metabolism</i> , <b>2022</b> ,	6.7	3
34	The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia.. <i>Current Atherosclerosis Reports</i> , <b>2022</b> , 24, 13	6	0
33	A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies.. <i>Metabolites</i> , <b>2022</b> , 12,	5.6	3
32	Nutrient sensing in the gut and the regulation of appetite. <i>Current Opinion in Endocrine and Metabolic Research</i> , <b>2022</b> , 100318	1.7	
31	Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Improves Eating Behavior and Glycemic Control in Japanese Obese Type 2 Diabetic Patients.. <i>Metabolites</i> , <b>2022</b> , 12,	5.6	0
30	New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation.. <i>Frontiers of Medicine</i> , <b>2022</b> , 16, 17	12	0
29	Semaglutide. <i>L Endocrinologo</i> , <b>2022</b> , 23, 204-207	0	
28	Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS).. <i>Diabetes Therapy</i> , <b>2022</b> , 13, 795	3.6	1
27	Semaglutide: a game changer for metabolic diseases?. <i>Exploration of Medicine</i> , 173-180	1.1	0
26	Oral semaglutide - Rybelsus <sup>®</sup> , the first GLP-1 receptor agonist for oral use in clinical practice. <i>Vnitřní Lekarství</i> , <b>2022</b> , 68, 89-95	0.3	
25	Role of endogenous incretins in the regulation of postprandial lipoprotein metabolism.. <i>European Journal of Endocrinology</i> , <b>2022</b> , 187, 75-84	6.5	0
24	Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis. <i>International Journal of Clinical Pharmacy</i> ,	2.3	0
23	Clinically Both Effects of Weight and Glucose Variability by Oral Semaglutide (Rybelsus) for Younger Female Patient with Type 2 Diabetes (T2D). <b>2022</b> , 11-14		
22	Population pharmacokinetic of paracetamol and atorvastatin with co-administration of semaglutide. <i>Pharmacology Research and Perspectives</i> , <b>2022</b> , 10,	3.1	
21	Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes. <i>Acta Diabetologica</i> ,	3.9	0

20	Current and emerging drugs for the treatment of atherosclerosis: the evidence to date. <i>Expert Review of Cardiovascular Therapy</i> , 1-13	2.5	○
19	Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease.		1
18	Serum-Derived Exosomal microRNAs in Lipid Metabolism in Polycystic Ovary Syndrome.		○
17	Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists.		○
16	Nanoparticle-assisted oral delivery of small and large peptides. <b>2022</b> , 131-166		○
15	Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. 13,		○
14	Normal and disordered gastric emptying in diabetes: recent insights into (patho)physiology, management and impact on glycaemic control.		1
13	DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce $\beta$ Synuclein Levels in the 6-OHDA Parkinson Disease Rat Model. <b>2022</b> , 2022, 1-11		○
12	Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea. <b>2022</b> , 1,		○
11	Mechanisms of GLP-1 Receptor Agonists on the Cardio-Renal Protective Effects. <b>2022</b> , 53, 249-262		○
10	Semaglutide delays 4-hour gastric emptying in women with PCOS and obesity.		1
9	Association of glucagon-like peptide -1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy.		○
8	Evaluation and prediction of oral drug absorption and bioequivalence with food-drug interaction. <b>2023</b> , 50, 100502		○
7	Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy. <b>2023</b> , 87, 111091		○
6	The gut odorant receptor and taste receptor make sense of dietary components: A focus on gut hormone secretion. 1-15		○
5	The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials. Volume 16, 575-595		○
4	Impact of novel glucose-lowering therapies on physical function in people with type 2 diabetes: A systematic review and meta-analysis of randomised placebo-controlled trials.		○
3	Semaglutide, vidange gastrique retardée et aspiration pulmonaire peropératoire : une présentation de cas.		○

- 2      Glucagon-like peptide-1 receptor agonists: role in the prevention and treatment of diabetes-related cardiovascular complications. **2023**, 365-396      ○
- 1      A bibliometric analysis and visualization of literature on non-fasting lipid research from 2012 to 2022. 14,      ○